Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NCI-2020-04587 | Registry Identifier | CTRP (Clinical Trial Reporting Program) | |
| 2020-0470 | Other Identifier | M D Anderson Cancer Center |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Cancer Institute (NCI) | NIH |
Not provided
Not provided
Not provided
Not provided
The primary purpose of this study is to gain an understanding of how experiences during the COVID-19 pandemic, regardless of COVID-19 status, may have impacted multiple domains of health-related quality of life and other areas such as COVID-19 specific psychological distress, and disruptions to health care, finances and social interactions. We will also evaluate the extent to which resiliency factors such as social support, perceived benefits under times of stress, and ability to manage stress may buffer associations between COVID-19 experiences and HRQoL. To meet these objectives, we have developed a 10-minute questionnaire that taps into these areas and is based on prior work addressing concerns of other pandemics or national crises. Participants will have previously consented to protocol PA15-0336 and have provided prior lifestyle data. This will allow us to connect the COVID-19 survey data with prior existing data.
PRIMARY OBJECTIVES:
I. Assess experiences during the COVID-19 pandemic (e.g., exposure, risk factors, testing, isolation, seropositivity, hospitalization, loss of family or friends); COVID-19-specific psychological distress (e.g., fear, anxiety and depressive symptoms); health, financial and social disruptions; perceived benefits and social support; and health-related quality of life (HRQoL) in melanoma patients who participated in protocol PA15-0336.
II. Evaluate the extent to which COVID-19 experiences are associated with COVID-19-specific psychological distress, health, financial and social disruptions, perceived benefits and social support, and HRQoL.
III. Evaluate the extent to which resiliency factors such as social support and perceived benefits moderate the effects of COVID-19 experiences on COVID-19-specific psychological distress and HRQoL.
IV. Explore the association between prior lifestyle data collected as part of PA15-0336 and COVID-19-specific psychological distress and HRQoL.
OUTLINE:
Patients complete a survey over 10 minutes.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Observational (survey administration) | Patients complete a survey over 10 minutes. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Survey Administration | Other | Complete survey |
|
| Measure | Description | Time Frame |
|---|---|---|
| Experiences during the COVID-19 pandemic | Including exposure, risk factors, testing, isolation, seropositivity, hospitalization, or loss of family or friends. | Survey completion Up to 2 months |
| COVID-19-specific psychological distress | Survey completion Up to 2 months | |
| COVID-19-specific health | Survey completion Up to 2 months | |
| COVID-19-specific financial and social disruptions | Survey completion Up to 2 months | |
| COVID-19-specific perceived benefits and social support | Survey completion Up to 2 months | |
| COVID-19-specific health related quality of life (HRQoL) | Survey completion Up to 2 months | |
| Effects of COVID-19 experiences on COVID-19-specific psychological distress and HRQoL | Will evaluate the extent to which resiliency factors such as social support and perceived benefits moderate the effects of COVID-19 experiences on COVID-19-specific psychological distress and HRQoL. | Survey completion Up to 2 months |
| Prior lifestyle data | Will explore the association between prior lifestyle data collected as part of PA15-0336 and COVID-19-specific psychological distress and HRQoL. | Survey completion Up to 2 months |
Not provided
Not provided
Inclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Patients who have signed consent for PA15-0336.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Lorenzo Cohen | Contact | (713) 745-4260 | lcohen@mdanderson.org |
| Name | Affiliation | Role |
|---|---|---|
| Lorenzo Cohen | M.D. Anderson Cancer Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| M D Anderson Cancer Center | Recruiting | Houston | Texas | 77030 | United States |
Not provided
| Label | URL |
|---|---|
| M D Anderson Cancer Center | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D008545 | Melanoma |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D018358 | Neuroendocrine Tumors |
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D009380 | Neoplasms, Nerve Tissue |
| D018326 | Nevi and Melanomas |
| D012878 | Skin Neoplasms |
| D009371 | Neoplasms by Site |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |